Myelofibrosis, JAK2 inhibitors and erythropoiesis
- 5 June 2013
- journal article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 27 (6), 1219-1223
- https://doi.org/10.1038/leu.2013.72
Abstract
No abstract availableThis publication has 55 references indexed in Scilit:
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia, 2013
- Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionThe Journal of Experimental Medicine, 2012
- Dnmt3a is essential for hematopoietic stem cell differentiationNature Genetics, 2011
- Orientation-specific signalling by thrombopoietin receptor dimersThe EMBO Journal, 2011
- New mutations and pathogenesis of myeloproliferative neoplasmsBlood, 2011
- Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid TransformationCancer Cell, 2011
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Leukemia, 2010
- JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficienciesSeminars in Cell & Developmental Biology, 2008
- The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraBlood, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005